Skip to main content

Table 4 Ongoing clinical trials combining epigenetic drugs and immune checkpoint blockade therapy in cancers

From: Immune checkpoint therapy in liver cancer

Cancer type Number Immune checkpoint inhibitors Epigenetic drugs Stage Status Design Trial NCT
HCC 90 Durvalumab Guadecitabine Phase 1 Recruiting Single Group Assignment NCT03257761
Unresectable NSCLC 41 Nivolumab and ipilimumab ACY-241 Phase 1 Recruiting Single Group Assignment NCT02635061
Metastatic unresectable HER2-negative breast cancer 45 Pembrolizumab Entinostat Phase 1 Recruiting Single Group Assignment NCT02453620
Advanced solid tumors 30 Pembrolizumab Entinostat Phase 1 Recruiting Randomized NCT02909452
Unresectable stage III/IV melanoma 17 Ipilimumab Panobinostat Phase 1 Recruiting Single Group Assignment NCT02032810
Advanced CRC 30 Pembrolizumab Romidepsin and/or 5-AZA Phase 1 Recruiting Randomized NCT02512172
MSS advanced CRC 30 Pembrolizumab Romidepsin and/or 5-AZA Phase 1 Recruiting Randomized NCT02512172
MDS following DNMTi-failed therapy 27 Pembrolizumab Entionstat Phase 1 Recruiting Single Group Assignment NCT02936752
Advanced solid tumors or lymphomas 45 Nivolumab RRx-001 Phase 1 Active, not recruiting Single Group Assignment NCT02518958
MM 19 Ipilimumab SGI-110 Phase 1 Recruiting Single Group Assignment NCT02608437
MDS 73 Durvalumab with or without tremelimumab Azacytidine Phase 1 Recruiting Non-Randomized NCT02117219
Advanced cell carcinoma 62 Atezolizumab Entinostat Phase 1/2 Recruiting Single Group Assignment NCT03024437
Breast cancer 88 Atezolizumab Entinostat Phase 1/2 Recruiting Randomized NCT02708680
DLBCL 5 Rituximab Belinostat Phase 2 Active, not recruiting Single Group Assignment NCT01686165
Metastatic uveal melanoma 29 Pembrolizumab Entinostat Phase 2 Recruiting Single Group Assignment NCT02697630
DLBCL 42 Rituximab Panobinostat Phase 2 Active, not recruiting Randomized NCT01238692
Advanced solid tumors and NSCLC 119 Durvalumab Mocetinostat Phase 1/2 Recruiting Single Group Assignment NCT02805660
NSCLC and melanoma 202 Pembrolizumab Entinostat Phase 1/2 Recruiting Non-Randomized NCT02437136
HNSCC and SGC 49 Pembrolizumab Vorinostat Phase 1/2 Active, not recruiting Single Group Assignment NCT02538510
Stage IV NSCLC 100 Pembrolizumab Vorinostat Phase 1/2 Recruiting Randomized NCT02638090
DLBCL 83 Rituximab Vorinostat Phase 1/2 Active, not recruiting Single Group Assignment NCT00972478
Lymphoma/leukaemia 40 Rituximab Vorinostat Phase 1/2 Active, not recruiting Single Group Assignment NCT00918723
Advanced renal or urothelial cell carcinoma 42 Pembrolizumab Vorinostat Phase 2 Recruiting Non-Randomized NCT02619253
Hormone therapy-resistant breast cancer 87 Pembrolizumab Vorinostat Phase 2 Recruiting Randomized NCT02395627
AML 182 Nivolumab 5-AZA Phase 2 Recruiting Non-Randomized NCT02397720
Metastatic CRC 31 Nivolumab 5-AZA Phase 2 Active, not recruiting Single Group Assignment NCT02260440
Advanced/metastatic NSCLC 100 Nivolumab 5-AZA Phase 2 Active, not recruiting Randomized NCT02546986
MDS 120 Nivolumab and/or ipilimumab 5-AZA Phase 2 Recruiting Non-Randomized NCT02530463
Refractory/relapsed AML 37 Lirilumab 5-AZA Phase 2 Active, not recruiting Single Group Assignment NCT02399917
MDS 12 Lirilumab and nivolumab 5-AZA Phase 2 Active, not recruiting Non-Randomized NCT02599649
Metastatic melanoma 71 Pembrolizumab 5-AZA Phase 2 Recruiting Non-Randomized NCT02816021
NSCLC 120 Nivolumab 5-AZA and/or entinostat Phase 2 Recruiting Randomized NCT01928576
NSCLC 60 Nivolumab 5-AZA- CdR/tetrahydrouridine Phase 2 Recruiting Randomized NCT02795923
Advanced solid tumors 60 Durvalumab 5-AZA Phase 2 Recruiting Single Group Assignment NCT02811497
Advanced/metastatic NSCLC 100 Pembrolizumab Oral azacytidine Phase 2 Active, not recruiting Randomized NCT02546986
PR recurrent OC 38 Pembrolizumab Guadecitabine Phase 2 Recruiting Single Group Assignment NCT02901899
PR recurrent OC 20 Pembrolizumab Oral azacytidine Phase 2 Recruiting Randomized NCT02900560
MDS 120 Durvalumab Oral azacytidine Phase 2 Recruiting Randomized NCT02281084
MDS, AML 213 Durvalumab Azacytidine Phase 2 Active, not recruiting Randomized NCT02775903
Refractory/recurrent epithelial OC 138 Avelumab Entinostat Phase 2 Recruiting Randomized NCT02915523
DLBCL 304 Rituximab 5-AZA Phase 3 Recruiting Randomized NCT02951156
  1. HCC hepatocellular carcinoma, NSCLC Non-small cell lung cancer, HER2 human epidermal growth factor receptor 2, CRC colorectal cancer, 5-AZA Azacitydine, MSS Microsatellite stable, MDS Myelodysplastic syndromes, DNMTi DNA methyltransferase inhibitor, MM Multiple myeloma, DLBCL Diffuse large B cell lymphoma, HNSCC head and neck squamous cell carcinoma, SGC salivary gland cancer, AML Acute myeloid leukaemia, OC ovarian cancer